Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

Trial Profile

Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Ciraparantag (Primary)
  • Indications Haemorrhage
  • Focus Therapeutic Use
  • Sponsors Perosphere
  • Most Recent Events

    • 16 Mar 2018 Planned End Date changed from 1 May 2018 to 1 Jul 2018.
    • 16 Mar 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2018.
    • 13 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top